Shots:
- Quotient has entered into a multi-year research collaboration agreement with Merck to discover novel drug targets in inflammatory bowel disease leveraging Quotient’s somatic genomics platform tech
- Through its somatic genomics platform, Quotient analyzes patient tissue to identify disease-causing or protective mutations, generating insights that inform novel therapeutic strategies across multiple conditions, including IBD
- As per the deal, Quotient will receive $20M upfront, along with development, regulatory & commercial milestone payments, representing the potential total deal value of ~$2.2B
Ref: Globenewswire| Image: Quotient Therapeutics & Merck | Press Release
Related News: Merck Carves Out Oncology as Standalone Division
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
